Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

v2.4.0.8
Condensed Consolidated Financial Statement Detail (Tables)
9 Months Ended
Sep. 30, 2013
Condensed Consolidated Financial Statement Detail [Abstract]  
Outstanding securities considered anti-dilutive
The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

 
 
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
 
 
2013
   
2012
   
2013
   
2012
 
Common stock options and restricted stock units
   
6,825
     
5,730
     
6,017
     
5,788
 
Warrants for common stock
   
15,970
     
16,626
     
16,106
     
12,942
 
Total
   
22,795
     
22,356
     
22,123
     
18,730
 

Accrued liabilities
Accrued liabilities consisted of the following at September 30, 2013 and December 31, 2012 (in thousands):

 
 
September 30,
2013
   
December 31,
2012
 
Accrued management incentive compensation
 
$
3,112
   
$
3,978
 
Accrued payroll and other benefits
   
2,708
     
2,461
 
Accrued clinical trial costs
   
500
     
4,702
 
Other
   
1,696
     
1,904
 
Total
 
$
8,016
   
$
13,045